A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

310

Participants

Timeline

Start Date

March 1, 2016

Primary Completion Date

July 28, 2020

Study Completion Date

April 27, 2021

Conditions
Soft Tissue Sarcoma
Interventions
DRUG

Olaratumab

Administered IV

DRUG

Gemcitabine

Administered IV

DRUG

Docetaxel

Administered IV

DRUG

Placebo

Administered IV

Trial Locations (48)

3000

Peter MacCallum Cancer Centre, Melbourne

5000

Royal Adelaide Hospital, Adelaide

Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz, Szolnok

10032

Columbia University Medical Center, New York

10060

Fondazione Piemonte l'Oncologia-Istituto Ricerca Cura Cancro, Candiolo

10065

Memorial Sloan Kettering Cancer Center, New York

10153

Humanitas Gradenigo, Torino

11042

Monter Cancer Center, Lake Success

13125

HELIOS Klinikum Berlin-Buch, Berlin

15526

Helios Klinikum Bad Saarow, Bad Saarow

21287

Johns Hopkins University School of Medicine, Baltimore

28041

Hospital Universitario 12 de Octubre, Madrid

28046

Hospital Universitario La Paz, Madrid

30342

Georgia Cancer Specialists PC, Atlanta

30625

Medizinische Hochschule Hannover, Hanover

32224

Mayo Clinic-Jacksonville, Jacksonville

33076

Institut Bergonie, Bordeaux

33136

Sylvester Comprehensive Cancer Center, Miami

41013

Hospital Universitario Virgen del Rocio, Seville

43210

Ohio State University Medical Center, Columbus

53226

Medical College of Wisconsin, Milwaukee

59020

Centre Oscar Lambret, Lille

63110

Washington University Medical School, St Louis

68114

Nebraska Methodist Cancer Center, Omaha

74146

Oklahoma Cancer Specialists & Research Institute, LLC, Tulsa

75390

University of Texas Southwestern Medical Center at Dallas, Dallas

77030

University of Texas MD Anderson Cancer Center, Houston

80045

University of Colorado Cancer Center, Aurora

81377

Klinikum der Universität München, München

84106

Utah Cancer Specialists, Salt Lake City

89081

Universitätsklinikum Ulm, Ulm

90404

UCLA Medical Center, Santa Monica

93053

Universitätsklinikum Regensburg, Regensburg

94805

Gustave Roussy, Villejuif

98109

Seattle Cancer Care Alliance, Seattle

3525408

Rambam Medical Center, Haifa

4941492

Rabin Medical Center, Petah Tikva

5265601

Sheba Medical Center, Tel Litwinsky

6423906

Tel Aviv Sourasky Medical Center, Tel Aviv

02215

Dana Farber Cancer Institute, Boston

19111-2497

Fox Chase Cancer Center, Philadelphia

37232-6307

Vanderbilt University Medical Center, Nashville

02-781

Centrum Onkologii-Instytut im Marii Sklodowskiej-Curie, Warsaw

08035

Hospital Universitari Vall d'Hebron, Barcelona

NW1 2BU

University College Hospital - London, London

SW3 6JJ

Royal Marsden NHS Trust, London

CH63 4JY

Clatterbridge Cancer Centre, Bebbington

EH4 2XU

Western General Hospital, Edinburgh

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02659020 - A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter